Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Russian lung cancer study reveals Real-World treatment patterns

NCT ID NCT05887011

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes how doctors in Russia treat inoperable lung cancer (NSCLC and SCLC) using chemoradiotherapy. Researchers will collect data from 2000 patients across 50 cancer centers to understand real-world practices and short-term outcomes. No new treatments are given; the goal is to learn from existing medical records.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include 2000 patients who received chemoradiotherapy (cCRT or sCRT) for the treatment of locally advanced NSCLC and SCLC in 50 largest oncology centers in Russian Federation. The total enrolment period will take up to 2 years. Information about specific NSCLC or SCLC treatments following CRT (e.g., durvalumab) will not be collected in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years old 2. Provision of written informed consent 3. Patient received at least one RT dose under prescribed CRT (concurrent or sequential) for definitive treatment of locally advanced NSCLC (stage II-III, unresectable or inoperable NSCLC, including locoregional recurrence and patient's refusal to undergo surgery) or LS-SCLC based on local MDT decision 4. Patient is currently undergoing RT (preferably no more than 10 doses) Exclusion Criteria: 1. Participation in another clinical study with an investigational product during the last 3 months 2. Confirmation that the subject was already included in this study before 3. Absence of written informed consent form 4. Data erroneously collected from subjects for which written consent is not available, will not be included in or will be deleted from the study database.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Unresectable /inoperable locally advanced (stage II-III) NSCLC and locally advanced LS-SCLC (stage I-III)

Contacts and locations

Locations

  • Research Site

    Arkhangelsk, Russia

  • Research Site

    Balashikha, Russia

  • Research Site

    Barnaul, Russia

  • Research Site

    Grozny, Russia

  • Research Site

    Irkutsk, Russia

  • Research Site

    Ivanovo, Russia

  • Research Site

    Kaluga, Russia

  • Research Site

    Kazan', Russia

  • Research Site

    Kemerovo, Russia

  • Research Site

    Khabarovsk, Russia

  • Research Site

    Khanty-Mansiysk, Russia

  • Research Site

    Kirov, Russia

  • Research Site

    Kostroma, Russia

  • Research Site

    Krasnodar, Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novokuznetsk, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Obninsk, Russia

  • Research Site

    Perm, Russia

  • Research Site

    Podolsk, Russia

  • Research Site

    Rostov-on-Don, Russia

  • Research Site

    Ryazan, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saransk, Russia

  • Research Site

    Saratov, Russia

  • Research Site

    Sochi, Russia

  • Research Site

    Tula, Russia

  • Research Site

    Tver', Russia

  • Research Site

    Ulyanovsk, Russia

  • Research Site

    Vladivostok, Russia

  • Research Site

    Vologda, Russia

  • Research Site

    Yakutia, Russia

  • Research Site

    Yaroslavl, Russia

  • Research Site

    Yekaterinburg, Russia

  • Research Site

    Yuzhno-Sakhalinsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.